The Malmberg lab partner in major cancer immunotherapy project
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
From major journals, first or last author from the Institute for Cancer Research
Lereim RR, Dunn C, Aamdal E, Chauhan SK, Straume O, Guren TK, Kyte JA(2024) Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival Oncoimmunology, 14(1), 2440967 DOI 10.1080/2162402X.2024.2440967, PubMed 39703053
Pinto R, Vedeld HM, Lind GE, Jeanmougin M(2024) Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework Mol Oncol(in press) DOI 10.1002/1878-0261.13772, PubMed 39696831
Farooqi SJ, Zhao Z, Öjlert ÅK, Thunold S, Juul HV, Bjaanæs MM, Horndalsveen H, Nymoen HMG, Helland Å, Haakensen VD(2024) Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma Front Immunol, 15, 1480183 DOI 10.3389/fimmu.2024.1480183, PubMed 39687621
Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry K, Holmes TW, Wang J, Huang CH, Ward A, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou Get al.(2024) A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer Cancer Res(in press) DOI 10.1158/0008-5472.CAN-24-0323, PubMed 39700396
Lereim RR, Dunn C, Aamdal E, Chauhan SK, Straume O, Guren TK, Kyte JA(2024) Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival Oncoimmunology, 14(1), 2440967 DOI 10.1080/2162402X.2024.2440967, PubMed 39703053
Pinto R, Vedeld HM, Lind GE, Jeanmougin M(2024) Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework Mol Oncol(in press) DOI 10.1002/1878-0261.13772, PubMed 39696831